Abingworth's early action

Abingworth's venture deal flow in the past 12 months reveals a clear preference for getting in early on companies that are generating pipelines of first- or best-in-class products. The latest biotech to match the profile is Tizona Therapeutics Inc., which raised $43 million in a series B round last week to advance antibody modulators of the tumor microenvironment into clinical testing.

New investors Abingworth and Canaan Partners co-led last week's oversubscribed round, and were joined by Lightstone Ventures and all of Tizona's existing investors: MPM, Amgen Ventures, Astellas Venture Management and InterWest. ...